These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 28535721)

  • 61. Biologic therapy in erythrodermic and pustular psoriasis.
    Levin EC; Debbaneh M; Koo J; Liao W
    J Drugs Dermatol; 2014 Mar; 13(3):342-54. PubMed ID: 24595581
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast.
    Chiricozzi A; Caposiena D; Garofalo V; Cannizzaro MV; Chimenti S; Saraceno R
    Expert Rev Clin Immunol; 2016; 12(3):237-49. PubMed ID: 26692125
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Occurrence of plantar pustular psoriasis during treatment with infliximab.
    English PL; Vender R
    J Cutan Med Surg; 2009; 13(1):40-2. PubMed ID: 19298770
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2).
    Crowley J; Thaçi D; Joly P; Peris K; Papp KA; Goncalves J; Day RM; Chen R; Shah K; Ferrándiz C; Cather JC
    J Am Acad Dermatol; 2017 Aug; 77(2):310-317.e1. PubMed ID: 28416342
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Infliximab for the treatment of recalcitrant generalized pustular psoriasis of pregnancy: Report of a challenging case.
    Babuna Kobaner G; Polat Ekinci A
    Dermatol Ther; 2020 Jul; 33(4):e13571. PubMed ID: 32406109
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Generalized Pustular Psoriasis: A Review of the Pathophysiology, Clinical Manifestations, Diagnosis, and Treatment.
    Reynolds KA; Pithadia DJ; Lee EB; Clarey D; Liao W; Wu JJ
    Cutis; 2022 Aug; 110(2 Suppl):19-25. PubMed ID: 36219603
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Clinical Course and Characteristics of Generalized Pustular Psoriasis.
    Choon SE; Navarini AA; Pinter A
    Am J Clin Dermatol; 2022 Jan; 23(Suppl 1):21-29. PubMed ID: 35061227
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The successful use of etanercept in combination therapy for treatment of acrodermatitis continua of hallopeau.
    Kazinski K; Joyce KM; Hodson D
    J Drugs Dermatol; 2005; 4(3):360-4. PubMed ID: 15898294
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity.
    Poulalhon N; Begon E; Lebbé C; Lioté F; Lahfa M; Bengoufa D; Morel P; Dubertret L; Bachelez H
    Br J Dermatol; 2007 Feb; 156(2):329-36. PubMed ID: 17223874
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials.
    Thaçi D; Kimball A; Foley P; Poulin Y; Levi E; Chen R; Feldman SR
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):498-506. PubMed ID: 27538241
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Treatment of acrodermatitis continua of hallopeau with ixekizumab.
    Miller AC; Holland TE; Cohen DJ
    J Dermatolog Treat; 2021 Feb; 32(1):117-119. PubMed ID: 31184530
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Systemic antipsoriatic combination therapy with fumaric acid esters for plaque-type psoriasis: report on 17 cases.
    Wilsmann-Theis D; Frambach Y; Philipp S; Weyergraf AJ; Jacobi A; Mössner R; Gerdes S
    Dermatology; 2015; 230(2):119-27. PubMed ID: 25661583
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naïve patients with psoriasis.
    Armstrong AW; Betts KA; Sundaram M; Thomason D; Signorovitch JE
    J Am Acad Dermatol; 2016 Oct; 75(4):740-746. PubMed ID: 27476973
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Predictors of long-term drug survival for infliximab in psoriasis.
    Magis Q; Jullien D; Gaudy-Marqueste C; Baumstark K; Viguier M; Bachelez H; Guibal F; Delaporte E; Karimova E; Montaudié H; Boye T; Aubin F; Beylot-Barry M; Richard MA;
    J Eur Acad Dermatol Venereol; 2017 Jan; 31(1):96-101. PubMed ID: 27325600
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Three years' experience with infliximab in recalcitrant psoriasis.
    Ahmad K; Rogers S
    Clin Exp Dermatol; 2006 Sep; 31(5):630-3. PubMed ID: 16901301
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Generalized pustular psoriasis: A global Delphi consensus on clinical course, diagnosis, treatment goals and disease management.
    Puig L; Choon SE; Gottlieb AB; Marrakchi S; Prinz JC; Romiti R; Tada Y; von Bredow D; Gooderham M
    J Eur Acad Dermatol Venereol; 2023 Apr; 37(4):737-752. PubMed ID: 36606566
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Unmet Medical Needs in the Treatment and Management of Generalized Pustular Psoriasis Flares: Evidence from a Survey of Corrona Registry Dermatologists.
    Strober B; Kotowsky N; Medeiros R; Mackey RH; Harrold LR; Valdecantos WC; Flack M; Golembesky AK; Lebwohl M
    Dermatol Ther (Heidelb); 2021 Apr; 11(2):529-541. PubMed ID: 33638115
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Treatment of recalcitrant pustular psoriasis with infliximab: effective reduction of chemokine expression.
    Benoit S; Toksoy A; Bröcker EB; Gillitzer R; Goebeler M
    Br J Dermatol; 2004 May; 150(5):1009-12. PubMed ID: 15149518
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
    Reich K; Gooderham M; Green L; Bewley A; Zhang Z; Khanskaya I; Day RM; Goncalves J; Shah K; Piguet V; Soung J
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):507-517. PubMed ID: 27768242
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
    Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
    J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.